## Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest

and a Waiver under 18 U.S.C.\\$208 (b)(3)				
John Bradley, M.D.				
Committees:	Anti-Infective Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee			
Meeting Date:	December 14-15, 2006			
I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the overall benefit to risk considerations for the approved product, Ketek (telithromycin), new drug application (NDA) 21-144, manufactured by Sanofi-Aventis with the current indications of acute bacterial exacerbations of chronic bronchitis, acute bacterial sinusitis, and community acquired pneumonia, I am eligible to receive a waiver under 18 U.S.C.§208 (b)(3).				
Type of Interest		Nature		Magnitude
Unrelated Consulting		Competing Firm		Less than \$10,001 per year
Unrelated Research Grant		Competing Firm		Less than \$100,000 per year
I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.				
/s/ Signature of SGE			_ <u>11/11/</u> Date	<u>'06</u>